As of 2025-11-05, the Relative Valuation of Neovacs SA (ALNEV.PA) is (279.25) EUR. This relative valuation is based on P/E multiples. With the latest stock price at 0.03 EUR, the upside of Neovacs SA based on Relative Valuation is -816608.9%.
The range of the Relative Valuation is (333.99) - (158.98) EUR.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 11.5x | 10.2x |
| Forward P/E multiples | 24.2x - 30.6x | 30.2x |
| Fair Price | (333.99) - (158.98) | (279.25) |
| Upside | -976677.0% - -464944.2% | -816608.9% |
| Date | P/E |
| 2025-10-29 | -0.00 |
| 2025-10-28 | -0.00 |
| 2025-10-27 | -0.00 |
| 2025-10-24 | -0.00 |
| 2025-10-23 | -0.01 |
| 2025-10-22 | -0.01 |
| 2025-10-21 | -0.01 |
| 2025-10-20 | -0.02 |
| 2025-10-17 | -0.01 |
| 2025-10-16 | -0.01 |
| 2025-10-15 | -0.01 |
| 2025-10-14 | -0.01 |
| 2025-10-13 | -0.01 |
| 2025-10-10 | -0.01 |
| 2025-10-09 | -0.01 |
| 2025-10-08 | -0.01 |
| 2025-10-07 | -0.01 |
| 2025-10-06 | -0.01 |
| 2025-10-03 | -0.01 |
| 2025-10-02 | -0.01 |
| 2025-10-01 | -0.01 |
| 2025-09-30 | -0.01 |
| 2025-09-29 | -0.01 |
| 2025-09-26 | -0.01 |
| 2025-09-25 | -0.01 |
| 2025-09-24 | -0.01 |
| 2025-09-23 | -0.02 |
| 2025-09-22 | -0.02 |
| 2025-09-19 | -0.02 |
| 2025-09-18 | -0.02 |
| 2025-09-17 | -0.02 |
| 2025-09-16 | -0.02 |
| 2025-09-15 | -0.02 |
| 2025-09-12 | -0.03 |
| 2025-09-11 | -0.03 |
| 2025-09-10 | -0.03 |
| 2025-09-09 | -0.03 |
| 2025-09-08 | -0.03 |
| 2025-09-05 | -0.04 |
| 2025-09-04 | -0.04 |
| 2025-09-03 | -0.04 |
| 2025-09-02 | -0.04 |
| 2025-09-01 | -0.05 |
| 2025-08-29 | -0.04 |
| 2025-08-28 | -0.04 |
| 2025-08-27 | -0.05 |
| 2025-08-26 | -0.05 |
| 2025-08-25 | -0.06 |
| 2025-08-22 | -0.05 |
| 2025-08-21 | -0.06 |